The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Skvortsova V.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Shetova I.M.

Ministry of Health of the Russian Federation, Moscow, Russia

Kakorina E.P.

Departament of health monitoring, analysis and strategic development Ministry of Health of the Russian Federation, Moscow, Russia

Kamkin E.G.

Boiko E.L.

Alekyan B.G.

Ivanova G.E.

Research Institute of cerebrovascular pathology and stroke SBEI HPE RNSMU N.I. Pirogov, Moscow, Russia

Shamalov N.A.

Research Institute of cerebrovascular pathology and stroke of the Pirogov Russian national research medical University, Moscow, Russia

Dash'jan V.G.

GBOU VPO «MGMSU im. A.I. Evdokimova» Minzdrava Rossii, Moskva;
GBUZ «NII skoroj pomoschi im. N.V. Sklifosovskogo» Departamenta zdravoohranenija Moskvy, Moskva

Krylov V.V.

FGBU MRNTs Minzdrava Rossii, Obninsk

Results of implementation of a «Complex of measures to improve medical care for patients with stroke in the Russian Federation»

Authors:

Skvortsova V.I., Shetova I.M., Kakorina E.P., Kamkin E.G., Boiko E.L., Alekyan B.G., Ivanova G.E., Shamalov N.A., Dash'jan V.G., Krylov V.V.

More about the authors

Read: 2638 times


To cite this article:

Skvortsova VI, Shetova IM, Kakorina EP, et al. . Results of implementation of a «Complex of measures to improve medical care for patients with stroke in the Russian Federation». S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4):5‑12. (In Russ.)
https://doi.org/10.17116/jnevro2018118415-12

Recommended articles:
Intracranial hype­rtension in hemo­rrhagic stroke: a single-center retrospective study. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):23-29
COVID-19 and pneumonia — mortality and coding features (example of the Moscow region). Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):30-39
Endo­vascular treatment and sele­ction criteria for acute mese­nteric ischemia. Piro­gov Russian Journal of Surgery. 2025;(2):13-19

References:

  1. Krishnamurthi RV, Feigin VL, Forouzanfar MHb, Mensah GA, Connor M on behalf of the Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990—2010: findings from the Global Burden of Disease Study 2010. The Lancet Global Health. 2013;1(5):259-281.
  2. Skvortsova VI, Stakhovskaya LV, Ayrian NYu. Stroke epidemiology in Russian. Consilium Medicum. 2005;7(1):4-9. (In Russ.)
  3. Stroke. A guide for doctors. Ed. Stakhovskoy LV, Kotova SV. M.: MIA; 2014. (In Russ.) National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator For Acute Ishemic Stroke. The New England Journal of Medicine. 1995;333(24): 47-52.
  4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, for the ECASS Study Group. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):53-59.
  5. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245-1251.
  6. Clark WM, Wissman S, Albers G, Jhamandas JH, Madden KP. for the ATLANTIS Study Investigators. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA. 1999;282:2019-2026.
  7. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med. 2008;359:131729.
  8. Berkhemer OA, Fransen PS, Beumer D,; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20.
  9. Goyal M, Demchuk AM, Menon BK,; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-1030.
  10. Jovin TG, Chamorro A, Cobo E; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-2306.
  11. Saver JL, Goyal M, Bonafe A; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285-2295.
  12. Campbell BC, Mitchell PJ, Kleinig TJ; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009-1018.
  13. Skvortsova VI, Golukhov GN, Gubskii LV, Shamalov NA, Sidorov AM, Bodykhov MK, Ramazanov GR, Yakimovich PV, Kireev AS. Systemic thrombolysis in ischemic stroke therapy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006;106:12:24-31. (In Russ)
  14. Skvortsova VI, Golukhov GN, Volynskiy YD, Gubskii LV, Shamalov NA, Kirillov MG. High efficiency of intraarterial selective thrombolysis in therapy of patients with large artery occlusion. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006;106:12: 32-40. (In Russ)
  15. Demin TV, Saykhunov MV, Khasanova DR. Systemic thrombolysis experience in ischemic stroke treatment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2010;1: 42-46. (In Russ.)
  16. Skvortsova VI, Shamalov NA, Anisimov KV, Ramazanov GR. The results of systemic thrombolysis introduction in ischemic stroke treatment in Russian Federation. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Insul’t). 2010;12:2:17-22. (In Russ)
  17. Bray BD, Campbell J, Cloud GC, Hoffman A, Tyrrell PJ, et al on behalf of the Intercollegiate Stroke Working Party Group. Bigger, Faster? Associations Between Hospital Thrombolysis Volume and Speed of Thrombolysis Administration in Acute Ischemic Stroke. Stroke. 2013;44:3129-3135.
  18. Kunisawa S, Kobayashi D, Lee J, Otsubo T, Ikai H, Yokota C, Minematsu K, Imanaka Y. Factors associated with the administration of tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(4):724-731.
  19. Katzan IL, Hammer MD, Hixson ED, Furlan AJ for the Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. Arch Neurol. 2004;61:346-350.
  20. Van Wijngaarden JD, Dirks M, Huijsman R, Niessen LW, Fabbricotti IN, Dippel DW. Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE) Investigators. Hospital rates of thrombolysis for acute ischemic stroke: the influence of organizational culture. Stroke. 2009;40(10):3390-3392.
  21. Boode B, Welzen V, Franke C, van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis. 2007;23(4):294-298.
  22. AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:121-128.
  23. http://193.232.7.120/feml/clinical_ref/0001410670S/HTML/
  24. https://clinicaltrials.gov/ct2/show/NCT01270867

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.